WAU
CRNX

Wellington-Altus USA’s Crinetics Pharmaceuticals CRNX Stock Holding History

Wellington-Altus USA’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11.3K Hold
310
– – 0.01% 570
2026
Q1 		$11.6K Sell
310
-85
-22% -$3.8K 0.01% 591
2025
Q4 		$18.4K Buy
+395
New +$17.6K 0.01% 500

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JT
Jupiter Topco New York $245B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wellington-Altus USA's CRNX Position: Q2 2026 in Review

Wellington-Altus USA held its Crinetics Pharmaceuticals (CRNX) position steady in Q2 2026 at 310 shares worth $11.3K. The position accounts for 0.01% of the portfolio, ranked #570.

Wellington-Altus USA first reported a position in CRNX in Q4 2025 and has held it in 3 quarters since. The position peaked at $18.4K in Q4 2025. 267 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

  • Wellington-Altus USA held 310 shares of Crinetics Pharmaceuticals worth $11.3K as of Q2 2026.
  • Wellington-Altus USA left its Crinetics Pharmaceuticals share count unchanged in Q2 2026.
  • Crinetics Pharmaceuticals made up 0.01% of Wellington-Altus USA's portfolio in Q2 2026, its #570 holding.
  • Wellington-Altus USA first reported a position in Crinetics Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • Wellington-Altus USA's Crinetics Pharmaceuticals position peaked at $18.4K in Q4 2025.
  • 267 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on Wellington-Altus USA's 13F filing for Q2 2026, filed 17 Sep 2026.